Voyager Therapeutics Inc (VYGR)
Healthcare
Biotechnology
3.00 $
-3.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Voyager Therapeutics Inc (VYGR)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 73.2% of the shares are freely tradable; institutional investors hold 56.4%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
56.4%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
15.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
73.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
7.1%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
60Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.22 | 5,568,381 | -0.9 | 03/31/2026 |
| Armistice Capital, LLC | 5.79 | 3,500,000 | -12.5 | 03/31/2026 |
| Millennium Management LLC | 5.67 | 3,428,571 | +82.3 | 03/31/2026 |
| Vanguard Group Inc | 5.41 | 3,266,484 | +0.5 | 12/31/2025 |
| Vestal Point Capital LP | 4.97 | 3,002,936 | +103.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.78 | 2,283,253 | +0.0 | 03/31/2026 |
| Opaleye Management Inc | 1.90 | 1,150,000 | -3.9 | 03/31/2026 |
| Erste Asset Management GmbH | 1.81 | 1,095,141 | -8.4 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 2.77 | 1,671,885 | +0.0 | 04/30/2026 |
| iShares Russell 2000 ETF | 1.88 | 1,137,647 | +0.9 | 05/29/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.